2012
DOI: 10.1016/s1474-4422(12)70140-0
|View full text |Cite
|
Sign up to set email alerts
|

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
179
0
2

Year Published

2013
2013
2022
2022

Publication Types

Select...
6
4

Relationship

1
9

Authors

Journals

citations
Cited by 257 publications
(184 citation statements)
references
References 29 publications
3
179
0
2
Order By: Relevance
“…Some progress is being made in developing vaccines which modulate the course of diabetes and hypertension [42]. Vaccination against addiction, including smoking, is also feasible, although very high antibody concentrations are required to achieve an effect [43], and there are early results suggesting that vaccination against Alzheimer's disease might slow the progress of this condition [44]. In the coming decades, vaccination is likely to expand its scope beyond prevention of the common infections of childhood which has been its main success so far.…”
Section: The Long-term Future Of Vaccinationmentioning
confidence: 99%
“…Some progress is being made in developing vaccines which modulate the course of diabetes and hypertension [42]. Vaccination against addiction, including smoking, is also feasible, although very high antibody concentrations are required to achieve an effect [43], and there are early results suggesting that vaccination against Alzheimer's disease might slow the progress of this condition [44]. In the coming decades, vaccination is likely to expand its scope beyond prevention of the common infections of childhood which has been its main success so far.…”
Section: The Long-term Future Of Vaccinationmentioning
confidence: 99%
“…The distinctive features of CSF, together with the low incidence of complications after lumbar puncture [62] have supported the introduction of lumbar puncture and analyses of CSF biomarkers into routine clinical practice in some centers [63,64]. CSF biomarkers are also increasingly used in clinical drug trials, both for enrichment of the target population at inclusion and to evaluate the biochemical effects of treatment [65][66][67].…”
Section: Cerebrospinal Fluid Biomarkersmentioning
confidence: 99%
“…An over-exuberant T cell response appears to have been responsible for the meningoencephalitis that was observed in patients [98,99]. New trials have therefore focused on active [100], or passive vaccination that does not stimulate a T cell response [101]. Two phase III trials using passive immunization against Aβ did not meet their primary endpoints, although Solanezumab did show a small but significant reduction of cognitive decline in those with mild dementia after pooling data from two clinical trials [102], and based on this it is being carried forward to Phase III studies.…”
Section: Extracellular Clearance Degradation and Prevention Of Uptamentioning
confidence: 99%